RetinalGenix Technologies Inc. Stock: price and insider trades · United States
US·Mcap US$75.2M
RetinalGenix Technologies Inc.: what insiders have been doing
Only a handful of insider records exist for RetinalGenix Technologies Inc., the last one from 10 June 2026, too few to describe a trend. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
1
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$3.99
Analyst consensus
Income statement
Gross profit-US$639.5k
EBITDA-US$2.4M
Net income-US$2.4M0.0% margin
Valuation
Beta-3.30
Balance sheet & cash
Market capUS$75.2M
Total debtUS$55.5k
Free Cash Flow-US$558.4k
Profitability & ownership
ROA-6411.5%
% insiders65.3%
% institutions0.0%
Last declaration on 10 June 2026
Declarations1 total
- 181,900 shares@ US$4.00100.0% of flowCommonSEC144:0001493152-26-028062
1 of 1 declaration
About RetinalGenix Technologies Inc.
RetinalGenix Technologies Inc. is a company focused on developing technological solutions for eye health. It is listed on NASDAQ under the ticker XNAS.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
